Fig. 1.

Neoadjuvant ipilimumab study design. Patients with locally and/or regionally advanced melanoma were enrolled and underwent excisional biopsy. They then received 2 cycles of ipilimumab 10 mg/kg every 21 days. A radical definitive surgery was then performed. Patients received 2 additional cycles of ipi 10 mg/kg every 21 days. Blood specimens (serum/peripheral blood monitoring) were collected at baseline, 6 weeks, 3, 6, and 9 months